Review of TCR-T Cell Therapy for Solid Tumors: Mechanisms and Clinical Progress

A 37.4 KB review document summarizes the biological basis and clinical progress of T-cell receptor-engineered T-cell therapy for solid tumors. Authored by Wenfang Hu and published under a CC-BY-4.0 license on figshare, the document was last updated on May 7, 2026. It discusses target selection, antigen-presentation barriers, and emerging strategies to improve therapeutic performance.

Use Cases

• Summarizing key biological mechanisms of TCR-T therapy based on the review of peptide-HLA recognition and tumor-cell killing.
• Identifying current clinical efficacy limitations based on the discussion of HLA restriction and immunosuppressive tumor microenvironment.
• Exploring future research directions based on the review of emerging strategies like precision receptor engineering and microenvironment-focused armoring.

Strengths

• Document is a focused review authored by a specific researcher (Wenfang Hu).
• Available under a permissive CC-BY-4.0 license for reuse.
• Last updated date (2026-05-07) suggests recent content.

Limitations

• The 37.4 KB file size indicates a limited scope, likely a single review article rather than a dataset.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect the author's perspective and selection bias inherent to a review document.

Provenance

Source

figshare

Freshness

Last updated 2026-05-07 04:37:16; freshness should be verified.